IMG Artificial Intelligence Technology

Sapient Announces Leadership Transition to Propel Next Phase of Growth and Innovation

Jonathan Usuka, Ph.D., Appointed Chief Executive Officer as Founder Mohit Jain, M.D., Ph.D., Transitions to Chief Scientific Officer

Sapient Announces Leadership Transition to Propel Next Phase of Growth and Innovation

Carla Nieser
Head of Marketing, Sapient
carla.nieser@sapient.bio
858.290.7010

Sapient, a leader in multi-omics discovery, today announced a strategic leadership transition aimed at continued acceleration of its growth and scientific impact. Jonathan Usuka, Ph.D., MBA, Sapient’s Chief Business Officer, will assume the role of Chief Executive Officer and Founder, Mohit Jain, M.D., Ph.D., will continue to serve as a member of the Sapient Board and transition to the role of Chief Scientific Officer. In his role, Dr. Jain will continue to focus on Sapient’s key scientific initiatives, including advancing state-of-the-art bioanalytics beyond the genome and large data AI to accelerate drug discovery. This leadership evolution aligns Sapient’s business and scientific visions, bringing together operational and scientific advancements to drive breakthrough discoveries in translational biology for Sapient’s partners across the pharmaceutical ecosystem.

“As Sapient’s Founder, I am dedicated to the company’s mission and am excited about our next phase impacting human health. Jonathan’s expertise in corporate strategy, data, and analytics will enable Sapient to scale under his leadership. As Chief Scientific Officer, I will focus on expanding our service offerings, in particular focusing on mass spectrometry-based proteomics and building our human tumor and plasma proteomics data assets. These unique data assets will be critical for unlocking valuable solutions for pharmaceutical discovery and serving our clients at the highest level. At the same time, I will continue to work closely with Jonathan in charting Sapient’s continued success,” said Dr. Jain.

Incoming CEO Dr. Jonathan Usuka expressed his enthusiasm for the role, stating: “Since joining Sapient, I have been inspired by our team’s commitment to revolutionizing multi-omics data at scale for drug discovery and development. I am honored to take on the CEO role leading the incredible scientists and employees at Sapient, and look forward to building upon the strong foundation Mo and the co-founders have established. I am confident we can expand Sapient’s impact, together with our talented team and partners.”

Peter Batesko, Sapient’s Lead Director and Managing Partner of Care Equity, commented: “Mo’s focus on driving impactful science and Jonathan’s appointment mark a pivotal point in Sapient’s evolution. We are appreciative of Mo’s continued visionary leadership since the company’s founding, and we’re confident Jonathan will continue expanding this vision and lead Sapient into its next phase of growth.”

About Jonathan Usuka, Ph.D.

Dr. Usuka brings over 25 years of experience at the intersection of science and business, with a history of scaling companies through innovation and data-driven solutions. His previous roles include leadership positions in pharmaceutical services and analytics at REALM IDx, McKinsey & Company, Roche, and Bristol Myers Squibb. His deep expertise will support Sapient’s ambitious goals for growth and impact.

About Sapient

Sapient is at the forefront of biomarker discovery, utilizing cutting-edge, high-throughput mass spectrometry and biocomputational frameworks to offer unparalleled multi-omics data generation and analysis. By enabling comprehensive biomarker-phenotype mapping across thousands of biosamples, Sapient empowers biopharma sponsors to advance precision drug development beyond genomic insights. Our Human Biology Database — comprising over 100,000 samples — enables rapid drug target identification, biomarker validation, and translational insights across all stages of drug development. For more information, visit sapient.bio.

Forward-Looking Statements

This press release includes forward-looking statements concerning Sapient’s anticipated leadership transition and future growth. Actual results may differ due to risks and uncertainties. Sapient assumes no obligation to update these statements.